1. Home
  2. CHCO vs AUPH Comparison

CHCO vs AUPH Comparison

Compare CHCO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$121.96

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.91

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCO
AUPH
Founded
1957
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
CHCO
AUPH
Price
$121.96
$15.91
Analyst Decision
Hold
Buy
Analyst Count
2
4
Target Price
$132.50
$17.25
AVG Volume (30 Days)
73.9K
1.1M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
2.87%
N/A
EPS Growth
13.18
5075.00
EPS
2.20
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
$5.16
$17.54
Revenue Next Year
$3.12
$15.74
P/E Ratio
$55.19
$64.08
Revenue Growth
N/A
20.38
52 Week Low
$113.21
$7.29
52 Week High
$133.59
$16.88

Technical Indicators

Market Signals
Indicator
CHCO
AUPH
Relative Strength Index (RSI) 45.03 52.83
Support Level $119.31 $14.28
Resistance Level $124.33 $16.38
Average True Range (ATR) 2.52 0.68
MACD -0.38 -0.03
Stochastic Oscillator 27.82 63.10

Price Performance

Historical Comparison
CHCO
AUPH

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: